More articles from Volume 28, Issue 2, 2012
Reactive lymphadenopathy in daily practice
Diffuse large B cell lymphoma: variants, subgroups and subtypes/entities
Problematic 'low grade' lesions in lymphoproliferative pathology
Problematic 'high grade' lesions in lymphoproliferative pathology
Classical Hodgkin lymphoma: Differential diagnosis and tumour microenvironment
Article views
Plasma cell proliferations
Tatjana Terzic
Published: 01.12.2011.
Biochemistry
Volume 28, Issue 2 (2012)
pp. 504-512;
Abstract
References
1.
Cd45 negative (usually) with a few cases expressing aLK1. 32 Literature.
2.
Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat rev Immunol. 2008;(1):22–33.
3.
Klein U, Cattoretti C, Shen G, Lia Q, Mo M, Ludwig T, et al. Transcription factor IrF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006;(7):773–82.
4.
Iida P, Butler M, Corradini P, Boccadoro M, Klein B. Chaganti rsK, dalla-Favera r. deregulation of MUM1/ IrF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;226–30.
5.
Garcia G, Garcia, Maestre L, Lucas E, Montes-Moreno S F, Victoria R, et al. PrdM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica. 2006;467–74.
6.
Toellner K, De Vinuesa C, Dr T, Maclennan I. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. j Exp Med. 2000;(6):813–22.
7.
Calame K. Immunology: end game for B cells. Nature. 2001;289–90.
8.
Sanderson Rd, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell reg. 1989;27–35.
9.
Hargreaves D, Hyman P, Lu T, Ngo V, Bidgol G, Yr Z. Littman dr, Cyster jG. a coordinated change in chemokine responsiveness guides plasma cell movements. j Exp Med. 2001;45–56.
10.
Klein U, Pasqualucci L. B-cell receptor signaling derailed in lymphomas. Immunol Cell Biol. 2010;(4):346–7.
11.
Higgins Ra, Blankenship Je, Kinney M. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med. 2008;441–61.
12.
Peterson L, Kueck B. Brunning rd. systemic polyclonal immunoblastic proliferations. Cancer. 1988;1350–8.
13.
Li L, Hsu P, Patel K, Y, I, Brody. Polyclonal plasma cell proliferation with marked hypergammaglobulinemia and multiple autoantibodies. Clin Lab sci. 2006;(4):479–84.
14.
Bj B, Dm C, Ia L, Bs W. Infections and reactive changes. 2001;(3).
15.
Kojima M, Murayama K, Igarashi T. Masawa N, shimano s, Nakamura s. Bone marrow plasmacytosis in idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia: a report of four cases. Pathol res Pract. 2007;(11):789–94.
16.
Ba P. Castleman disease. Curr Opin Hematol. 2007;354–9.
17.
Campo E, Harris N. WHO classification of tumours of haematopoietic and lymphoid tissues. 2008;200–13.
18.
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International MyelomaWorking Group. Br j Haemotol. 2003;749–57.
19.
Kyle Ra, Therneau T, Offord Jr, Larson Dr, Plevak M, Joseph Melton Lj L. a long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl j Med. 2002;564–9.
20.
Ruiz G. Cell surface markers in multiplemyeloma. Mayo Clin Proc. 1994;684–90.
21.
Ely Sa, Knowles Dm. Expression of Cd56 ⁄ neural adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. am j Pathol. 2002;1293–9.
22.
Owen Rg M, Gj. Phenotyping in myeloma: identification of a rare Cd19+ Cd56subgroup. Blood. 2000;156.
23.
Martín P, Bellas C. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Histopathology. 2004;(4):375–80.
24.
Bataille G, Robillard N, Barillé-Nion S, Harousseau Jl, Moreau P, M. Pellat-deceunynck C. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica. 2006;1234–40.
25.
Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. Clin Oncol. 2005;6339–44.
26.
Menke Dm, Horny H, Griesser H, Tiemann M, Katzmann Ja E, Kaiserling E, et al. Primary lymph node plasmacytomas (Plasmacytic lymphomas). am j Clin Pathol. 2001;119–26.
27.
Campo E, Harris N, Pileri S, Stein H, Es. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;5019–32.
28.
Wilkins B, Buchan, Webster. Tryptase-positive mast cells accompany lymphocytic as well as lymphoplasmacytic lymphoma infiltrates in bone marrow trephine biopsies. Histopathology. 2001;150–5.
29.
Berger F, Traverse-Glehen A, Felman P, Callet-Bauchu E, Baseggio L, Gazzo, Thieblemont C, et al. Clinicopathologic features of Waldenstrom’s macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity? Clin Lymphoma. 2005;220–4.
30.
Teruya-Feldstein j. diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol rep. 2005;357–63.
31.
Delecluse Hj I, Dallenbach F, Hummel M, Marafioti T, Schneider U, Huhn D, Schmidt-Westhausen A, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;1413–20.
32.
Colomo L, Loong F, Pittaluga, Martínez. López-Guillermo a, Ojanguren j, romagosa V, jaffe Es, Campo E. diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. am j surg Pathol. 2004;736–47.
33.
Vega F, Chang C, Lj M, Udden M, Cho-Vega Jh, Lau C, et al. Vilchez ra, McGregor d, jorgensen jL. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;806–15.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
